A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Completed · Phase 1

Conditions studied: Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma

In brief

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

Key facts

Study ID

NCT03013218

Run by

ALX Oncology Inc.

People needed

174

Starts

2017-02-03

Expected to finish

2025-07-08

Last updated by the study team

2025-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..
• Adequate Bone Marrow Function.
• Adequate Renal \& Liver Function.
• Adequate Performance Status

You may not qualify if…

• Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.
• Previous high-dose chemotherapy requiring allogenic stem cell rescue.
• Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.

Where it is running

• University of Colorado Denver — Denver, Colorado, United States
• Yale University — New Haven, Connecticut, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• START-Midwest — Grand Rapids, Michigan, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• Seoul National University Bundang Hospital — Seongnam, South Korea
• Samsung Medical Center — Seoul, South Korea
• Seoul National University Hospital — Seoul, South Korea
• Severance Hospital, Yonsei University — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.